Phoenix, Arizona-based Creative Medical Technology Holdings Inc. (CELZ:NASDAQ) provided clinical and operational updates across its pipeline of cell-based therapies, noted Roth MKM analyst Dr. Jonathan Aschoff in a November 15 research report.
Aschoff reiterated a Buy rating and US$30 price target on Creative Medical.
Multiple Clinical Programs Progressing
Creative Medical is advancing Phase 1/2 trials of CELZ-201-DDT for chronic lower back pain and CELZ-201 for type 1 diabetes. The company also reported positive one-year data for CELZ-001 in type 2 diabetes.
According to Aschoff, CELZ-201-DDT showed over 90% pain reduction and 80% narcotics reduction in a pilot study, supporting the upcoming Phase 1/2 trial. Enrollment is underway for the CELZ-201 type 1 diabetes study.
The analyst sees Creative Medical's ImmCelz platform, which activates a patient's own cells, as a key value driver. The company made progress optimizing ImmCelz and expects to enter the clinic for autoimmune disorders.
Funded Through 2024 with Over US$12 Million Cash
Creative Medical maintained a strong cash position of US$12 million at the end of Q3 2023, providing a runway through 2024 based on the analyst's estimates.
Significant Upside from Regenerative Medicine Pipeline
Roth Capital's US$30 price target on Creative Medical implies over 600% upside potential for the stock. The firm's valuation is based on a discounted cash flow analysis of projected revenues from the company's pipeline candidates.
In summary, the analyst sees Creative Medical's progress across multiple cell therapy programs, combined with its cash balance, as positioning the company for upside as data catalysts approach.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for Roth MKM, Creative Medical Technology Holdings Inc., November 15, 2023
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Disclosures: ROTH makes a market in shares of Creative Medical Technology Holdings, Inc. and as such, buys and sells from customers on a principal basis. ROTH and/or its employees, officers, directors and owners own options, rights or warrants to purchase shares of Creative Medical Technology Holdings, Inc. stock. Shares of Creative Medical Technology Holdings, Inc. may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities. Roth or its affiliates beneficially own(s) 1% or more of an equity security of Creative Medical Technology Holdings, Inc..
ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2023. Member: FINRA/SIPC.
